Kyongbo Pharmaceutical Co Ltd operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Kyongbo Pharmaceutical Co Ltd with three other
companies in this sector in KOREA (SOUTH) :
Kolon Life Science Incorporation
sales of 148.54 billion Korean Won [US$126.41 million]
of which 98%
(176.50 billion Korean Won [US$150.20 million]
of which 95%
was Medicine), and
(168.76 billion Korean Won [US$143.62 million]
During the year ended December of 2019, sales at
Kyongbo Pharmaceutical Co Ltd were 191.71 billion Korean Won (US$163.14 million).
decrease of 4.8%
versus 2018, when the company's sales were 201.34 billion Korean Won .
Contributing to the drop in overall sales was the 38.5% decline
in Cefa Api, from 69.05 billion Korean Won to 42.49 billion Korean Won .
There were also decreases in sales in
Other Raw Material (down 4.6% to 27.54 billion Korean Won )
Carcinostatis Substance Api (down 6.8% to 3.19 billion Korean Won )
Kyongbo Cefaclor Cap (down 17.7% to 1.19 billion Korean Won )
However, these declines were partially offset by the increase in sales of
General Api (up 27.2% to 71.43 billion Korean Won )
Other Finished Goods (up 7.0% to 40.29 billion Korean Won )
Sojourn Inhalation Anesthetics (up 13.5% to 2.91 billion Korean Won )
Rosueze Tab (up 22.1% to 2.66 billion Korean Won )